Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
NurExone Biologic Inc. is a clinical-stage biotechnology company focused on the development of regenerative therapies based on exosome technology. The company operates within the biotechnology and regenerative medicine industries, with a primary emphasis on treatments for central nervous system (CNS) injuries, particularly acute spinal cord injury. Its core therapeutic approach involves the use of biologically engineered exosomes designed to deliver therapeutic molecules that modulate inflammation and promote neural repair.
The company’s lead development program centers on an exosome-based therapy intended to improve recovery following traumatic spinal cord injury, addressing an area with significant unmet medical need and limited approved treatment options. NurExone positions itself through proprietary exosome engineering and targeted delivery methods, aiming to achieve therapeutic efficacy while minimizing systemic exposure. The company was incorporated in 2020 and has advanced from preclinical research into early clinical development, leveraging academic research origins and international scientific collaboration to support its evolution.
Business Operations
NurExone’s operations are primarily organized around research and development activities related to exosome-based therapeutics. Its main business line is the discovery, preclinical validation, and clinical development of biologic drug candidates, with future revenue expected to be derived from regulatory approvals, licensing arrangements, or commercialization partnerships. As of publicly available disclosures, the company does not report commercial product revenue and remains development-stage.
The company conducts R&D through internal teams and external collaborations, including academic institutions and contract research organizations. NurExone maintains operations in both Canada and Israel, reflecting its corporate headquarters and scientific base. It controls proprietary exosome production and loading technologies, and it operates through at least one wholly owned subsidiary, Exo-Top Inc., which is associated with manufacturing and process development activities; however, the full operational scope of this subsidiary is not comprehensively detailed in public filings.
Strategic Position & Investments
Strategically, NurExone is focused on advancing its lead spinal cord injury program toward clinical proof of concept while expanding the potential application of its exosome platform to additional CNS and inflammatory indications. Growth initiatives emphasize clinical trial execution, intellectual property expansion, and potential strategic partnerships with larger pharmaceutical or biotechnology companies.
The company has disclosed ongoing investment in scalable exosome manufacturing capabilities and delivery technologies. Its technology portfolio is intended to support both internal drug development and possible out-licensing opportunities. Beyond its core spinal cord injury focus, NurExone has indicated interest in broader regenerative and neuroinflammatory indications; however, specific additional product candidates or late-stage acquisitions have not been conclusively verified in public sources and remain data inconclusive based on available public sources.
Geographic Footprint
NurExone operates primarily across North America and the Middle East. The company is headquartered in Canada, with its common shares listed on the TSX Venture Exchange, providing access to Canadian capital markets. Its executive management and corporate functions are largely based in Canada.
Scientific research and development activities are significantly anchored in Israel, where the company benefits from proximity to academic research institutions and biomedical talent. While NurExone does not report commercial operations across other continents, its clinical development strategy and intellectual property filings suggest an intended global market reach, particularly in North America and Europe, subject to regulatory approvals.
Leadership & Governance
NurExone was founded based on academic research originating from Israeli scientific institutions, with Prof. Dan Peer widely recognized as a scientific founder due to his foundational work in exosome technology. The company is led by executives with experience in biotechnology development, translational research, and corporate governance, emphasizing a strategy centered on scientific rigor and disciplined clinical advancement.
Key members of leadership include:
- Dr. Lior Shaltiel – Chief Executive Officer
- Dr. Tamar Biran – Chief Financial Officer
- Prof. Dan Peer – Scientific Founder
- Dr. Racheli Ofir – Director and Scientific Advisor
The leadership team’s stated strategic vision focuses on translating advanced exosome science into clinically validated therapies while building long-term shareholder value through partnerships, intellectual property development, and regulatory progress.